Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis

Fig. 3

Apoptosis analysis of MS275 treated cancer cells. FITC-Annexin V and propidium iodide (PI) cell apoptotic assay of S180 (A, C) and H22 (B, D) cells after treatment with 0 μM, 2.5 μM, 5 μM, 10 μM MS275 for 36 h. The number of apoptotic cells stained with Annexin V/PI was measured by flow cytometry. Late apoptotic cell counts in the upper right quadrant (Q2) and early apoptotic cell counts in lower right quadrant (Q3) for different treatment groups. Apoptosis cell percentage in (C) equal s the sum of Q2 and Q3. **, P < 0.01 versus control group, Error bars represent SEMs of at least three independent measurements

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us